Amyloid beta and tau fight over the same spot on brain cell scaffolding - and that may be what drives Alzheimer's

Amyloid beta and tau proteins compete for the same binding sites on the structural scaffolding inside neurons. That single finding, reported by Ryan R. Julian and colleagues at the University of California, Riverside, may reconcile two theories of Alzheimer's disease that have divided the field for decades.

Two proteins, two camps, one disease

The amyloid hypothesis holds that the accumulation of amyloid beta plaques outside neurons is the primary driver of Alzheimer's disease. The tau hypothesis counters that it is the formation of neurofibrillary tangles - twisted clumps of tau protein inside neurons - that actually kills brain cells. Both camps have extensive evidence. Neither has produced a fully satisfying therapeutic strategy. Drugs targeting amyloid plaques have shown modest benefit at best. Tau-focused therapies are still largely experimental.

The new study proposes that the problem is not amyloid aggregation or tau aggregation per se, but something upstream of both: the displacement of tau from microtubules by amyloid beta.

Microtubules: the neuronal highway

Microtubules are cylindrical protein structures that form the internal scaffolding of neurons. They serve as highways for transporting molecules, organelles, and signaling components along the length of nerve cells - which, in the case of motor neurons, can stretch more than a meter. Tau protein normally stabilizes these microtubules, binding to their surface and preventing them from collapsing.

When tau detaches from microtubules, two things happen. The microtubules become unstable, disrupting intracellular transport. And the freed tau molecules aggregate into the neurofibrillary tangles that are a hallmark of Alzheimer's pathology. The question has always been: what causes tau to detach?

Amyloid beta binds where tau binds

Julian's team used fluorescence polarization to measure how tightly fluorescently labeled amyloid beta (both the 1-40 and 1-42 forms) binds to individual tubulin proteins and to assembled microtubules. The binding affinities they measured were comparable to those previously reported for tau - meaning amyloid beta grabs onto microtubules with roughly the same strength as the protein that is supposed to be there.

Sequence analysis using three different alignment algorithms confirmed structural similarity between amyloid beta and the microtubule-binding domains of tau. The two proteins, despite their different origins and functions, share enough structural features to recognize the same molecular docking sites.

The critical experiment was a competitive binding assay. When the researchers introduced recombinant human tau into the system, it reduced - but did not eliminate - amyloid beta binding to microtubules. This is consistent with shared or overlapping binding sites: the two proteins are literally competing for the same molecular real estate.

The microtubule nexus hypothesis

The authors call their framework the microtubule nexus hypothesis. The logic runs as follows: as amyloid beta accumulates (for whatever initial reason - impaired clearance, overproduction, aging-related changes), it begins to displace tau from microtubules. The displaced tau is free to misfold and aggregate into tangles. The microtubules, stripped of their tau stabilizer and now studded with amyloid beta that does not stabilize them effectively, begin to degrade. Intracellular transport fails. The neuron deteriorates.

This model does not require amyloid plaques or tau tangles as the primary toxic events. Instead, both are downstream consequences of the competitive displacement of tau from microtubules. The plaques and tangles are symptoms of the real problem, not the cause.

Rationalizing contradictions

If correct, the hypothesis resolves several long-standing puzzles. It explains why amyloid plaques and tau tangles co-occur in Alzheimer's - they share a common upstream cause. It explains why targeting plaques alone has produced disappointing therapeutic results - removing plaques does not reverse the displacement that has already occurred or restore tau to microtubules. And it explains why some individuals accumulate significant amyloid burden without developing dementia - if their tau binding is sufficiently robust, displacement may be limited.

The authors note that their findings are supported by and help rationalize previous studies that had indirectly examined interactions between amyloid beta and microtubules but had not been synthesized into a unified framework.

Implications and open questions

The therapeutic implications are significant. If the critical event in Alzheimer's is the competitive displacement of tau from microtubules, then interventions that strengthen tau-microtubule binding or prevent amyloid beta from accessing those binding sites could represent a fundamentally new treatment approach. Microtubule-stabilizing agents, some of which are already in development for other conditions, might have relevance.

But this is early-stage biochemistry. The binding experiments were conducted in vitro - in purified protein systems, not inside living neurons or human brains. Whether competitive displacement occurs at the concentrations and conditions present in an aging human brain remains to be demonstrated. The cellular environment is vastly more complex than a test tube, with hundreds of other proteins, post-translational modifications, and regulatory mechanisms that could modulate the interaction.

The study was conducted at UC Riverside and adds a new dimension to one of the most intensely studied diseases in medicine.